|
|
|
|
Diagnostic Test for OCD
Callisto is currently looking to out-license a diagnostic test for Obsessive
Compulsive Disorder (OCD). According to the National Institute of Mental
Health, OCD occurs in about one in fifty Americans, and OCD related social
and economic costs exceed $8 billion annually. In the United States and
Western Europe, 3 million children are screened for OCD each year. There
is currently no laboratory test available to diagnose OCD, and Callisto
believes its diagnostic test, designed to identify a marker for the disease
in affected patients, will assist psychiatrists in establishing the appropriate
medical and/or psychological treatment. Callisto has identified a molecular
marker, designated D8/17, consistently and selectively present on the immune
cells of OCD patients. The marker can be detected with a monoclonal antibody
which is patent protected. Two independent clinical trials with
more than 100 subjects, published in the American Journal of Psychiatry,
confirm the validity and utility of Callisto’s diagnostic marker for
OCD.
|
|
|
technology Links
|
|